Form 4: Dermata Director Bradrick Granted Stock Options

Dermata Therapeutics Director Brittany Bradrick was granted 2,500 stock options with an exercise price of $2.18, vesting over 12 months.

Summary

• Brittany Bradrick, a Director of Dermata Therapeutics, Inc. (DRMA), was granted 2,500 stock options.
• The stock options have an exercise price of $2.18 per share.
• The grant date for these options was January 2, 2026.
• The options will vest in twelve (12) substantially equal monthly installments, with the first installment vesting on February 2, 2026, subject to continuous service.
• The options expire on January 1, 2036.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a routine compensation event, aligning director interests with shareholders, but does not indicate significant operational news or a major shift in company prospects.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director to the company's success.

Negatives

• No immediate negative financial impact or operational concerns are disclosed in this specific filing.

Risks

• The value of the stock options is contingent on Dermata Therapeutics' common stock price exceeding the $2.18 exercise price in the future.
• The options are subject to a vesting schedule, requiring the director's continuous service to fully realize the benefit, and may be forfeited if service terminates prematurely.

Future Outlook

The grant of stock options with a 12-month vesting schedule suggests an expectation of continued service from the director and a long-term view on the company's performance and potential for stock price appreciation.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive compensation. This mechanism aligns the interests of company leadership with shareholder value creation and aids in director retention, reflecting standard corporate governance practices for publicly traded companies.

Comparison to Industry Standards

• The grant of 2,500 stock options to a director is a standard form of equity compensation within the industry.
• The exercise price of $2.18 is typically set at the market price of the common stock on the grant date, which is a common industry practice.
• A 12-month vesting period for director options is relatively short compared to some industry peers where vesting might extend over 3-4 years or be immediate. However, it is not uncommon, especially for smaller grants or specific compensation structures.
• The $0 price of the derivative security itself is standard for compensatory option grants, meaning the options were granted as part of a compensation package rather than purchased.

Stakeholder Impact

• Shareholders: Potential long-term alignment of the director's interests with shareholder value through equity ownership. The grant represents a minor potential future dilution if all options are exercised.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The stock options will begin vesting in monthly installments starting February 2, 2026.
• The director will continue to hold these options, subject to continuous service, until their expiration on January 1, 2036, or until exercised.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to an existing director as part of their compensation. While it serves to align the director's interests with those of shareholders, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this a standard compensation event and look to other filings for more substantive company updates.

Keywords

Dermata Therapeutics, DRMA, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Brittany Bradrick, SEC Form 4